Lycopene in the prevention of prostate cancer

Journal of the Society for Integrative Oncology

Volumn 6, Issue 1, 2008, Pages 29-36

  Dahan, Karen ^a   Fennal, Mildred ^b   Kumar, Nagi B ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b FLORIDA A AND M UNIVERSITY   (United States)

Author keywords

Lycopene; Prostate cancer

Indexed keywords

ALPHA TOCOPHEROL; ASCORBIC ACID; BETA CAROTENE; CAROTENOID; INTERLEUKIN 6; LYCOPENE; SOMATOMEDIN C; STEROID 5ALPHA REDUCTASE; XANTHOPHYLL;

ANTIOXIDANT ACTIVITY; APOPTOSIS; CANCER PREVENTION; CANCER RISK; CELL CYCLE ARREST; CHEMICAL ANALYSIS; CLINICAL TRIAL; DIET SUPPLEMENTATION; DIETARY INTAKE; DNA DAMAGE; GENE EXPRESSION; HUMAN; NONHUMAN; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATECTOMY; REVIEW; TOMATO; TUMOR CELL; TUMOR XENOGRAFT;

ANIMALS; ANTICARCINOGENIC AGENTS; CAROTENOIDS; CLINICAL TRIALS AS TOPIC; HUMANS; MALE; PROSTATIC NEOPLASMS;

EID: 41349110225     PISSN: 1715894X     EISSN: None     Source Type: Journal    
DOI: 10.2310/7200.2008.0001     Document Type: Review

References (58)

1. American Cancer Society. Cancer facts and figures. Atlanta: American Cancer Society; 2007.
2. Kumar NB, Cantor A, Allen K, et al. The specific role of isoflavones in reducing prostate cancer risk. Prostate 2004;59:141-7.
3. Holmberg L, Bill-Axelson A, Garmo H, et al, SPCG-4 Study Group. Prognostic markers under watchful waiting and radical prostatectomy. Hematol Oncol Clin North Am 2006;20:845-55.
4. Johansson JE, Andren O, Andersson SO, et al. Natural history of early, localized prostate cancer. JAMA 2004;291:2713-9.
5. Kelloff GJ, Leiberman R, Steele VE, et al. Chemoprevention of prostate cancer. Eur Urol 1999;35:342-50.
6. Klotz L. Active surveillance versus radical treatment for favorable-risk localized prostate cancer. Curr Treat Options Oncol 2006;7:355-62.
7. Miller DC, Gruber SB, Hollenbeck BK, et al. Incidence of initial local therapy among men with lower-risk prostate cancer in the United States. J Natl Cancer Inst 2006;98:1134-41.
8. Adams J, Kauffman M. Development of the proteasome inhibitor Velcade (bortezomib). Cancer Invest 2004;22:304-11.
9. Kantoff P. Prevention, complementary therapies, and new scientific developments in the field of prostate cancer. Rev Urol 2006;8 Suppl 2:S9-14.
10. Fleshner NE, Klotz LH. Diet, androgens oxidative stress and prostate cancer susceptibility. Cancer Metastasis Rev 2004;17:325-30.
11. Goyal A, Delves GH, Chopra M, et al. Prostate cells exposed to lycopene in vitro liberate lycopene-enriched exosomes. BJU Int 2006;98:907-11.
12. Gester H. The potential role of lycopene for human health. J Am Coll Nutr 1997;16:109-26.
13. Stahl W, Sies H. Lycopene: a biologically important carotenoid for humans? Arch Biochem Biophys 1996;336:1-9.
14. Nguyen ML, Schwartz SJ. Lycopene: chemical and biological properties. Food Technol 1999;53:38-45.
15. Kristal AR. Vitamin A, retinoids, and carotenoids as chemopreventive agents for prostate cancer. J Urol 2004;171(Part 2):S54-8.
16. Canene-Adams K, Campbell JK, Zaripheh S, et al. The tomato as a functional food. J Nutr 2005;135:1226-30.
17. Bowen P, Chen L, Stacewicz-Sapuntzakis M, et al. Tomato sauce supplementation and prostate cancer: lycopene accumulation and modulation of biomarkers of carcinogenesis. Exp Biol Med (Maywood) 2002;227:886-93.
18. Mourvaki E, Gizzi S, Ruggero R, Rufini S. Passionflower fruit - a "new" source of lycopene? J Med Food 2005;8:104-6.
19. Edwards AJ, Vinyard BT, Wiley ER, et al. Consumption of watermelon juice increases plasma concentrations of lycopene and beta-carotene in humans. J Nutr 2003;133:1043-50.
20. Perkins-Veazie P, Collins JK. Carotenoid changes of intact watermelon after storage. J Agric Food Chem 2006;54:5868-74.
21. Giovannuci E. Tomato products, lycopene, and prostate cancer: a review of the epidemiological literature. J Nutr 2005;135:2030S-1S.
22. Clinton SK. Tomatoes or lycopene: a role in prostate carcinogenesis? J Nutr 2005;135:2057S-9S.
23. Clinton SK, Emenhiser C, Schwartz SJ, et al. Cis-trans lycopene isomers, carotenoids, and retinol in the human prostate. Cancer Epidemiol Biomarkers Prev 1996;5:823-33.
24. Stahl W, Schwarz W, Sundquist AR, Sies H. Cis-trans isomers of lycopene and beta-carotene in human serum and tissues. Arch Biochem Biophys 1992;294:173-7.
25. Giovannuci E. Tomatoes, tomato-based products, lycopene, and cancer: review of the epidemiologic literature. J Natl Cancer Inst 1999;91:317-31.
26. Giovannuci E, Rimm EB, Liu Y, et al. A prospective study of tomato products, lycopene, and prostate cancer risk. J Natl Cancer Inst 2002;94:391-8.
27. Wu K, Erdman JW, Jr, Schwartz SJ, et al. Plasma and dietary carotenoids, and the risk of prostate cancer: a nested case-control study. Cancer Epidemiol Biomarkers Prev 2004;13:260-9.
28. Etminan M, Takkouche B, Caamano-Isorna F. The role of tomato products and lycopene in the prevention of prostate cancer: a meta-analysis of observational studies. Cancer Epidemiol Biomarkers Prev 2004;13:340-5.
29. Jian L, Du C, Lee AH, Binns CW. Do dietary lycopene and other carotenoids protect against prostate cancer? Int J Cancer 2005;113:1010-14.
30. Gann PH, Ma J, Giovannucci E, et al. Lower prostate cancer risk in men with elevated plasma lycopene levels: results of a prospective analysis. Cancer Res 1999;59:1225-30.
31. Rao AV, Fleshner N, Agarwal S. Serum and tissue lycopene and biomarkers of oxidation in prostate cancer patients: a case-control study. Nutr Cancer 1999;33:159-64.
32. Lu QY, Hung JC, Heber D, et al. Inverse associations between plasma lycopene and other carotenoids and prostate cancer. Cancer Epidemiol Biomarkers Prev 2001;10:749-56.
33. Kirsh VA, Mayne ST, Peters U, et al. A prospective study of lycopene and tomato product intake and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2006;15:92-8.
34. Peters U, Leitzmann MF, Chatterjee N, et al. Serum lycopene, other carotenoids, and prostate cancer risk: a nested case-control study in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. Cancer Epidemiol Biomarkers Prev 2007;16:962-8.
35. Boileau AC, Merchen NR, Wasson K, et al. Cis-lycopene is more bioavailable than trans-lycopene in vitro and in vivo in lymph-cannulated ferrets. J Nutr 1999;129:1176-81.
36. Siler U, Barella L, Spitzer V, et al. Lycopene and vitamin E interfere with autocrine/paracrine loops in the Dunning prostate cancer model. FASEB J 2004;18:1019-21.
37. Herzog A, Siler U, Spitzer V, et al. Lycopene reduced gene expression of steroid targets and inflammatory markers in normal rat prostate. FASEB J 2005;19:272-4.
38. Tang L, Jin T, Zeng X, Wang JS. Lycopene inhibits the growth of human androgen-independent prostate cancer cells in vitro and in BALB/c nude mice. J Nutr 2005;135:287-90.
39. Campbell JK, Stroud CK, Nakamura MT, et al. Serum testosterone is reduced following short-term phytofluene, lycopene, or tomato powder consumption in F344 rats. J Nutr 2006;136:2813-9.
40. Imaida K, Kuzutani K, Wang J, et al. Lack of promotion of 7,12-dimethylbenz[a]anthracene-initiated mouse skin carcinogenesis by 1.5 GHz electromagnetic near fields. Carcinogenesis 2001;22:1837-41.
41. Guttenplan JB, Chen M, Kosinska W, et al. Effects of a lycopene-rich diet on spontaneous and benzo[a]pyrene-induced mutagenesis in prostate, colon and lungs of the lacZ mouse. Cancer Lett 2001;164:1-6.
42. Obermuller-Jevic UC, Olano-Martin E, Corbacho AM, et al. Lycopene inhibits the growth of normal human prostate epithelial cells in vitro. J Nutr 2003;133:3356-60.
43. Cohen LA. Nutrition and prostate cancer: a review. Ann N Y Acad Sci 2002;963:148-55.
44. Liu A, Pajkovic N, Pang Y, et al. Absorption and subcellular localization of lycopene in human prostate cancer cells. Mol Cancer Ther 2006;5:2879-85.
45. Goyal A, Delves GH, Chopra M, et al. Can lycopene be delivered into semen via prostasomes? In vitro incorporation and retention studies. Int J Androl 2006;29:528-33.
46. Chan JM, Stampfer MJ, Giovannucci E, et al. Insulin-like growth factor I (IGF-I), IGF-binding protein-3 and prostate cancer risk: epidemiological studies. Growth Horm IGF Res 2000;10 Suppl A:S32-3.
47. Barber NJ, Zhang X, Zhu G, et al. Lycopene inhibits DNA synthesis in primary prostate epithelial cells in vitro and its administration is associated with a reduced prostate-specific antigen velocity in a phase II clinical study. Prostate Cancer Prostatic Dis 2006;9:407-13.
48. Pastori M, Pfander H, Boscoboinik D, Azzi A. Lycopene in association with alpha-tocopherol inhibits at physiological concentrations proliferation of prostate carcinoma cells. Biochem Biophys Res Commun 1998;250:582-5.
49. Kotake-Nara E, Kushiro M, Zhang H, et al. Carotenoids affect proliferation of human prostate cancer cells. J Nutr 2001;131:3303-6.
50. Forbes K, Gillette K, Sehgal I. Lycopene increases urokinase receptor and fails to inhibit growth or connexin expression in a metastatically passaged prostate cancer cell line: a brief communication. Exp Biol Med (Maywood) 2003;228:967-71.
51. Edinger MS, Koff WJ. Effect of the consumption of tomato paste on plasma prostate-specific antigen levels in patients with benign prostate hyperplasia. Braz J Med Biol Res 2006;39:1115-9.
52. Chen L, Stacewicz-Sapuntzakis M, Duncan C, et al. Oxidative DNA damage in prostate cancer patients consuming tomato sauce-based entrees as a whole-food intervention. J Natl Cancer Inst 2001;93:1872-9.
53. Kucuk O, Sarkar FH, Sakr W, et al. Phase II Randomized clinical trial of lycopene supplementation before radical prostatectomy. Cancer Epidemiol Biomarkers Prev 2001;10(8):861-8.
54. Ansari MS, Gupta NP. A comparison of lycopene and orchidectomy vs orchidectomy alone in the management of advanced prostate cancer. BJU Int 2004;94:678.
55. Clark PE, Hall MC, Borden LS, Jr, et al. Phase I-II prospective dose-escalating trial of lycopene in patients with biochemical relapse of prostate cancer after definitive local therapy. Urology 2006;67:1257-61.
56. Ansari MS, Gupta NP. Lycopene: a novel drug therapy in hormone refractory metastatic prostate cancer. Urol Oncol 2004;22:415-20.
57. Jatoi A, Burch P, Hillman D, et al. A tomato-based, lycopene-containing intervention for androgen-independent prostate cancer: results of a phase II study from the North Central Cancer Treatment Group. J Urol 2007;69:289-94.
58. Shao A, Hathcock JN. Risk assessment for the carotenoids lutein and lycopene. Regul Toxicol Pharmacol 2006;45:289-98.